IP Library › Granted Patent US 12,435,154
Granted Patent B2
US 12,435,154 · App. 17/314,946 · Granted Oct 7, 2025

Bispecific antibodies against CD3 and CD20

Inventors: Tahamtan Ahmadi (Rydal, PA); Manish Gupta (Skillman, NJ); Tommy Li (Edison, NJ); Roberto Oliveri (Copenhagen, DK); Dena Demarco (Chatham, NJ); Ida Hiemstra (Utrecht, NL); Christopher Chiu (Warren, NJ); Brian Elliott (Hoboken, NJ); Ada Azaryan (North Bethesda, MD)
Assignee: GENMAB A/S
C07K16/2887A61K31/573A61K39/3955A61K45/06A61P35/00C07K16/2809A61K39/00A61K2039/505A61K2039/545C07K2317/21C07K2317/24C07K2317/31
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,154
App. No.
17/314,946
Granted
Oct 7, 2025
Kind
B2
Abstract

The present invention relates to bispecific antibodies (bsAbs) and the use of such antibodies in the treatment of disease in subjects. Moreover, advantageous treatment regimens are provided for the treatment of B-cell Non-Hodgkin Lymphoma (B-NHL).

Claims (31)

1. A method of treating a B-cell non-Hodgkin lymphoma (B-NHL) in a human subject, the method comprising subcutaneously administering a dose of 0.16 mg of epcoritamab to the subject on day one (1) of treatment and subcutaneously administering a dose of 0.8 mg of epcoritamab to the subject on day eight (8) of treatment,

wherein the subject does not experience cytokine release syndrome (CRS) or experiences manageable cytokine release syndrome of grade 1 or grade 2, and

wherein after day eight (8) of treatment epcoritamab is subcutaneously administered in intervals to the subject until progressive disease develops or unacceptable toxicity occurs.

2. The method of claim 1 , wherein 48 mg of epcoritamab is administered subcutaneously to the human subject on days 15 and 22 of treatment.

3. The method of claim 2 , wherein said B-NHL is selected from the group consisting of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal-zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL), and wherein the patient achieves a complete response (CR).

4. The method of claim 3 , wherein said B-NHL is diffuse large B-cell lymphoma (DLBCL).

5. The method of claim 3 , wherein said B-NHL is mantle cell lymphoma (MCL).

6. The method of claim 3 , wherein said B-NHL is follicular lymphoma (FL).

7. The method of claim 3 , wherein said B-NHL is marginal-zone lymphoma (MZL).

8. The method of claim 3 , wherein said B-NHL is small lymphocytic lymphoma (SLL).

9. The method of claim 3 , wherein said B-NHL is relapsed or refractory B-NHL.

10. The method of claim 3 , wherein said B-NHL is chronic lymphocytic lymphoma (CLL).

11. The method of claim 1 , wherein 24 mg of epcoritamab is administered subcutaneously to the human subject on days 15 and 22 of treatment.

12. The method of claim 11 , wherein said B-NHL is selected from the group consisting of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal-zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL), and wherein the patient achieves a complete response (CR).

13. The method of claim 11 , wherein said B-NHL is diffuse large B-cell lymphoma (DLBCL).

14. The method of claim 11 , wherein said B-NHL is mantle cell lymphoma (MCL).

15. The method of claim 11 , wherein said B-NHL is follicular lymphoma (FL).

16. The method of claim 11 , wherein said B-NHL is marginal-zone lymphoma (MZL).

17. The method of claim 11 , wherein said B-NHL is small lymphocytic lymphoma (SLL).

18. The method of claim 11 , wherein said B-NHL is relapsed or refractory B-NHL.

19. The method of claim 11 , wherein said B-NHL is chronic lymphocytic lymphoma (CLL).

20. The method of claim 1 , wherein said B-NHL is selected from the group consisting of diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal-zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL).

21. The method of claim 20 , wherein said B-NHL is diffuse large B-cell lymphoma (DLBCL).

22. The method of claim 20 , wherein said B-NHL is mantle cell lymphoma (MCL).

23. The method of claim 20 , wherein said B-NHL is follicular lymphoma (FL).

24. The method of claim 20 , wherein said B-NHL is marginal-zone lymphoma (MZL).

25. The method of claim 20 , wherein said B-NHL is small lymphocytic lymphoma (SLL).

26. The method of claim 20 , wherein said B-NHL is relapsed or refractory B-NHL.

27. The method of claim 20 , wherein said B-NHL is chronic lymphocytic lymphoma (CLL).

28. The method of claim 1 , wherein prior to the day 1 of treatment with epcoritamab the human subject has received at least one prior line of treatment for the B-NHL.

29. The method of claim 1 , wherein prior to the day 1 of treatment with epcoritamab the human subject has received at least two prior lines of treatment for the B-NHL.

Assignments (3)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB HOLDING B.V.; GENMAB A/S; GENMAB B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2021
From: AHMADI, TAHAMTAN; GUPTA, MANISH; LI, TOMMY; OLIVERI, ROBERTO; DEMARCO, DENA; HIEMSTRA, IDA; CHIU, CHRISTOPHER; ELLIOTT, BRIAN; AZARYAN, ADA
To: GENMAB A/S
Reel/Frame 057356/0928 →
Cited By (1)
US 12,692,320